GF
APGE icon

Gabelli Funds’s Apogee Therapeutics APGE Stock Holding History

Gabelli Funds’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9M Buy
+127,281
New +$11.5M 0.11% 236

Other funds holding APGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MSE
MUFG Securities EMEA London, United Kingdom $9.53B AUM 52.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Gabelli Funds's APGE Position: Q2 2026 in Review

Gabelli Funds opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 127,281 shares worth $16.9M. The stake represents 0.11% of the portfolio and ranks #236 among its holdings.

130 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Gabelli Funds held 127,281 shares of Apogee Therapeutics worth $16.9M as of Q2 2026.
  • Apogee Therapeutics was a new Gabelli Funds position in Q2 2026.
  • Apogee Therapeutics made up 0.11% of Gabelli Funds's portfolio in Q2 2026, its #236 holding.
  • 130 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Gabelli Funds's 13F filing for Q2 2026, filed 12 Aug 2026.